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Phenobarbital-inducible cytochrome P450 variants have a higher affinity (app. K, = 0.6 for metyra- 
do variants (app. K, 80 PM). The difference in has 
enabled us to quantitate, by 
in liver microsomal membranes. result obtained by this simple, rapid 
by more sophisticated as radioimmunoassay and 
immunoprecipitation. 
1. INTRODUCTION 
Cytochrome is a major component of 
liver microsomal mixed-function 
and plays in the metabolism of 
and fatty acids, the detoxification of 
and xenobiotics and the activation of 
[l-3]. The range of me- 
tabolised, with the that the 
activities and proper- 
ties cytochrome P450 when animals 
treated with inducers of suggested 
the of multiple of this This 
has confirmed by purification of 
different cytochrome variants to homoge- 
neous 14-61. The of the 
nisms by different cytochrome variants 
are by various requires meth- 
for the quantitation of specific 
variants. 
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Phenobarbital Microsomes of rat liver 
Metyrapone, a potent inhibitor of steroid 1 l/3- 
hydroxylation in mitochondria [7,8] and of de- 
methylation of p-nitroanisol in microsomes [9], has 
been used as a probe to identify phenobarbital 
(PB)-inducible cytochrome P45Os because of the 
high affinity of reduced PB-inducible P450 to that 
reagent [7-121. However, in those studies, metyra- 
pone was used only in terms of qualitative analysis 
but not in terms of quantitative analysis. In [13] a 
molar extinction coefficient of metyrapone- 
reduced P450 complex was reported using purified 
PB-inducible P450. 
Here, we describe the use of spectral changes on 
binding of metyrapone to quantitate the major PB- 
inducible cytochrome P450 variant in liver micro- 
somal membranes from PB-treated and control 
rats. The results obtained by this simple method 
are compared with those from more sophisticated 
techniques such as immunoprecipitation and 
radioimmunoassay. 
2. MATERIALS AND METHODS 
2.1. Pretreatment of rat with phenobarbital 
Male Sprague-Dawley rats (200-250 g body wt) 
were injected intraperitoneally (i.p.) once a day for 
4 days with a 4% (w/v) solution of sodium phe- 
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nobarbital (PB) in 0.9% (w/v) NaCl at 40 mg/kg. 
Rats were starved overnight before use. 
2.2. Isolation and solubilisation of microsomal 
membrane vesicles 
Total microsomal membrane vesicles were iso- 
lated from liver homogenates as in [ 141 and stored 
in small aliquots at -78 “C until use. 
Cytochrome P450 was solubilised from microso- 
ma1 membrane vesicles with buffered sodium cho- 
late [ 151 or buffered Renex 690-cholate mixture as 
in [14]. 
2.3. Spectral analysis of metyrapone binding 
Metyrapone [2-methyl-1,2-bis(3-pyridyl)-l-pro- 
panone]-induced ifference spectra of reduced cy- 
tochrome P450 were examined as in [ 111. The sam- 
ple containing microsomal membrane vesicles 
(2 ml), 1 PM with respect o cytochrome P450, was 
reduced with -2 mg sodium dithionite, and the 
pH adjusted to 7.8 with 1 N NaOH. The resultant 
preparation was divided equally between 2 cu- 
vettes. A known quantity of metyrapone (Sigma) 
dissolved in water was added in c 10 ~1 to the sam- 
ple cuvette and an equal volume of water added to 
the reference cuvette. All difference spectral anal- 
yses were performed at room temperature in a 
Perkin-Elmer Hitachi double wave-length spectro- 
photometer model 556 equipped with a baseline 
corrector accessory. 
Apparent spectral dissociation constants (K,) of 
metyrapone-P450 complex were calculated by 
plots of the reciprocal of the absorbance difference 
(A&&-490) against the reciprocal of the metyra- 
pone concentration. 
2.4. Determination of cytochrome P450 and protein 
content in microsomes 
Total amounts of cytochrome P450 in microso- 
ma1 membrane suspension were determined by the 
CO-reduced difference spectral method [ 161 using 
an extinction coefficient of 91 mM-* . cm-l for 
AA450-490. Protein concentrations were deter- 
mined as in [17] using bovine serum albumin as 
the standard. 
2.5. Preparation of antibodies and immunochemical 
analysis 
Anti’oodies against the major PB-inducible cyto- 
chrome P450 (M, 52 000) were raised in rabbit and 
the immunoglobulin G fraction was isolated using 
a column of Bio-Rad DEAE Affl-gel Blue as in 
[ 141. Immunoprecipitation analysis and radioim- 
munoassay of the PB-inducible P450 (MI 52 000 
cytochrome P450) were done as in [ 141. 
3. RESULTS AND DISCUSSION 
3.1. Titration of cytochrome P4.50 in microsomes 
with metyrapone 
The binding curve was biphasic (fig.1). The 
large increase in absorbance in the first phase 
(fig.lA) virtually plateaued at 10 PM metyrapone 
and was followed by smaller changes in the second 
phase which were complete at 1 mM metyrapone 
(fig.lB). We interpret this data in terms of the evi- 
dence of two sets of metyrapone binding sites in 
microsomal membranes from PB-treated rats with 
very different affinity constants for the ligand. The 
inserts in fig.1 show that it is possible to. calculate 
app. &-values for the two sets of sites of -0.6 PM 
and - 80 PM, respectively. The titration of micro- 
somes from uninduced animals by metyrapone is 
shown in fig.2. The two sets of metyrapone binding 
sites are present and the app. Z&-value for the set 
of sites of lower affinity was calculated to be 
75 PM from data at > 100 PM metyrapone (see 
fig.2 insert) which is very close to one of the values 
obtained for the PB-induced microsomes (80 PM). 
Comparing our results with relevant data in the 
literature, the app. &-value of the metyrapone 
complex of purified PB-inducible cytochrome 
P450 was reported to be 1.8 PM [ 131; the KS values 
of similar complexes of cytochrome P450 and 
metyrapone in microsomal vesicles from PB- 
treated rats were reported as 0.7 PM [18] or 24 PM 
[9]. It seems reasonable to assume that the high 
affinity binding sites we measure are derived from 
PB-inducible cytochrome P450 and the lower af- 
finity sites relate to other uninduced cytochrome 
P45Os. 
3.2. Relationship between CO-cytochrome P450 
complex and metyrapone-cytochrome P450 
complex in microsomal membrane vesicles from 
uninduced rats 
Fig.3 shows a plot of the difference absorbance 
at 446 nm of the metyrapone-cytochrome P450 
complex vs that at 450 nm of the CO-cytochrome 
P450 complex in uninduced rat liver microsomes. 
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Fig.1. Spectral titration of reduced cytochrome P450 in 
microsomes from PB-treated rat liver with metyrapone. 
The experiments were done as in section 2 employing 
various concentrations of metyrapone: (A) < IO PM 
metyrapone; (B) 10 yM-1.4 mM metyrapone. The ex- 
tent of formation of metyrapone binding to cytochrome 
P450 was measured by the AA446 after each successive 
addition of metyrapone. Inserted figures show double 
reciprocal plots of each titration. 
The concentration of metyrapone used in this case 
was 1 mM. From the linear relationship and using 
a molar extinction coefficient of 0.091 M-1 . cm-l 
for A&u-490 of CO-cytochrome P450 complex, a 
molar extinction coefficient of 0.021 M-t . cm-l 
was calculated for the metyrapone complex of 
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Fig.2. Spectra1 titration of reduced cytochrome P450 in 
microsomes from untreated rat liver with metyrapone. 
The experiments were done as in section 2 using un- 
treated rat liver microsomes: (-) titration of reduced 
cytochrome P450 with metyrapone; (---) calculated titra- 
tion curve assuming a single K, of 75 PM. The insert 
shows a double reciprocal plot of data obtained at 
z 100 PM metyrapone. 
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Fig.3. Relationship between difference absorbance of 
metyrapone-reduced cytochrome P450 complex (AA446- 
490) and CO-reduced cytochrome P450 (AA450_490) in 
microsomes from untreated rat liver. Metyrapone was 
added to 1 mM final cont. to fully ligate all cytochrome 
P450 present in untreated rat liver microsomes. 
non PB-inducible cytochrome P450. This value is 
- % that reported for the molar extinction coeffi- 
cient of a metyrapone complex of purified PB-in- 
ducible cytochrome P450 (0.052 M-1 . cm-t) [13]. 
The difference may be due to the presence in unin- 
duced rat microsomes of non PB-inducible cyto- 
chromes P450 which do not bind metyrapone. The 
molar extinction coefficients were used for the es- 
timation of PB-inducible P450 and non PB-induci- 
ble cytochromes P450 in microsomes from PB- 
treated and control uninduced rats. 
3.3. The estimation of the amount of PB-inducible 
cytochrome P450 in microsomal membrane 
fractions 
Based on the difference in the affinity of PB- 
inducible cytochromes P450 and non PB-inducible 
cytochromes P450 for metyrapone (figl), at 10 PM 
and 1 mM was chosen, and the molar extinction 
coefficient of 0.052 M-t . cm-l in [13] and 
0.021 M-t . cm-t here were employed to estimate 
the relative amounts in microsomes of PB-induci- 
ble cytochromes P450 and the group of non PB- 
inducible cytochromes P450, respectively. The fol- 
lowing were taken into account: 
(I) At 10 PM metyrapone, all the PB-inducible cy- 
tochromes P450 were combined with metyra- 
pone (fig.l), whereas only 13% of non PB-in- 
ducible cytochromes P450 complexes with 
metyrapone (fig.2, ---). 
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Table 1 
Estimation of PB-inducible cytochrome P450 in rat liver microsomes 
Animals 
CO-P450 complex 
Specific content 
of total P450 
Metyrapone-P450 
c&446-490) 
10 pMa 1 mMa 
% of PB-inducible P45Ob 
Metyrapone- Immunopre- Radioimmuno- 
binding cipitation assay 
method methodC methodC 
PB-treated 1.64d 0.0380 0.0433 53 60 86 
rat 31.2e 
Untreated 0.82d 0.007 0.02 15 11 11 11 
rat 12.67e 
a Each value is the final concentration of metyrapone used; total cytochrome P450 cont. in each sample of rat liver 
microsomes investigated was - 1 PM 
b Values are expressed as the percentage of the total cytochrome P450 which is PB-inducible in each sample of rat liver 
microsomes 
C Data from [ 141; dnmol/mg microsomal protein; enmol/g liver 
(2) At 1 mM metyrapone, both PB-inducible and 
non PB-inducible cytochromes P450 combine 
completely with metyrapone. 
Under these conditions, the percentage of total 
cytochromes P450 that is PB-inducible was calcu- 
lated to be -53% in PB-treated rat microsomes 
and - 11% in untreated rat microsomes. The addi- 
tion of amounts of PB-inducible P450 and non PB- 
inducible P450 thus calculated nearly equalled 
(96%) the total amount of cytochrome P450 calcu- 
lated by the CO difference method, thus giving 
credence to the metyrapone-binding method. 
Using a radial immunodiffusion assay with mono- 
specific antibodies for PB-inducible cytochrome 
P450, figures similar to ours were obtained [ 191 for 
the amount of PB-inducible cytochrome P450 
present in PB-treated or untreated rat liver micro- 
somes. In [20], Ouchterlony double-immunodiffu- 
sion showed that PB-inducible cytochrome P450 is 
present in microsomes of untreated rats. 
Table 1 summarizes the quantitative data for the 
induction of PB-inducible cytochrome P450 by PB, 
as investigated by various methods. Injection of 
rats with PB increased the specific content of total 
cytochromes P450 2-fold in terms of cytochrome 
P450 content/mg microsomal protein, and 3-fold 
in terms of cytochrome P450 content/g liver. As 
reported in immunoprecipitation studies [ 141, 
-60% and - 11% of cytochrome P450 in PB-treat- 
ed and untreated rat microsomes, respectively, 
were precipitated with anti (PB-inducible P450) 
immunoglobulin G, suggesting - 16-fold induc- 
tion of PB-inducible cytochrome P45O/g liver [ 141. 
In radioimmunoassay studies, 9.6% of the protein 
and 86% of total cytochromes P450 in PB-treated 
microsomes, and 0.6% of the protein and 11% of 
total cytochromes P450 in untreated microsomes 
were identified as a PB-inducible cytochrome P450 
[ 141. This indicates an -24-fold increase in a PB- 
inducible cytochrome P45O/g liver. The 24-fold in- 
duction of PB-inducible P450 in vivo also corre- 
sponded well with the 18-fold induction of the 
mRNA coding for this specific P450 as reported in 
[141. 
These results indicate that if the conditions are 
controlled very carefully the metyrapone-binding 
technique serves as a simple and convenient meth- 
od to estimate, without the use of antibodies, the 
cytochromes P450 specifically induced by PB in rat 
liver microsomes, and consequently may be useful 
in the investigation of the mechanisms of PB in- 
duction of cytochrome P450. 
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